Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Derek Sheader
Latest news
-
LifeArc joins the REMEDi4ALL Consortium, a pioneering global platform shaping the future of drug repurposing
-
£1million partnership aims to develop new treatments for congenital muscular dystrophy
-
Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies